Praxis Precision Medicines, Inc. (NASDAQ: PRAX)

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing precision therapies for central nervous system, or CNS, disorders rooted in neuronal excitation-inhibition imbalance. The company leverages genetic insights from rare epilepsies to create targeted treatments for broader neurological conditions, including movement disorders and epilepsy. Praxis operates through two proprietary drug discovery platforms, Cerebrum and Solidus, which enable the development of small molecule and antisense oligonucleotide, or ASO, therapies, respectively. These platforms support a diversified pipeline of clinical and preclinical candidates designed to address significant unmet medical needs in underserved patient populations.

Praxis Precision Medicines generates revenue through partnerships, milestone payments, and potential future commercialization of its drug candidates. The company has entered into licensing agreements, such as its collaboration with UCB Biopharma SRL for PRAX-020 and Tenacia Biotechnology for ulixacaltamide in specific Asian markets. Additionally, Praxis may receive payments tied to regulatory and developmental milestones, as well as royalties from commercial sales of approved therapies. While the company has not yet commercialized any products, its near-term revenue potential hinges on the success of its lead candidates, ulixacaltamide and relutrigine, both of which have submitted New Drug Applications, or NDAs, to the U. S. Food and Drug Administration, or FDA.

The company operates through the following segments:

• Cerebrum: This segment focuses on the discovery and development of small molecule therapies targeting ion channels and other neuronal excitability mechanisms. Cerebrum has yielded three clinical-stage candidates, ulixacaltamide, vormatrigine, and relutrigine, as well as PRAX-020, which was in-licensed by UCB. The platform employs computational and experimental tools to design orally available therapies with precision targeting, aiming to improve efficacy and tolerability over existing treatments. Cerebrum’s candidates address conditions such as essential tremor, developmental and epileptic encephalopathies, or DEEs, and focal onset seizures.

• Solidus: This segment specializes in the development of antisense oligonucleotides, or ASOs, using a proprietary computational workflow to optimize drug-like properties. Solidus’s lead candidate, elsunersen, targets SCN2A-DEE and is currently in Phase 3 clinical trials. The platform has also generated three preclinical ASOs expected to enter development in 2026, targeting PCDH19 mosaic expression disorders, SYNGAP1 loss-of-function mutations, and SCN2A loss-of-function mutations. Solidus is positioned to deliver disease-modifying therapies for genetic CNS disorders with high unmet needs.

Praxis Precision Medicines occupies a distinctive position within the neuroscience biopharmaceutical industry, competing in markets with limited therapeutic options and high unmet needs. The company’s primary competitors include large pharmaceutical firms and specialized biotechnology companies developing treatments for epilepsy and movement disorders, such as SK-Pharma, Xenon Pharmaceuticals, Biohaven Pharmaceuticals, Lundbeck, and Stoke Therapeutics. Praxis differentiates itself through its precision medicine approach, leveraging genetic insights to identify and validate therapeutic targets with greater specificity. Its proprietary platforms, Cerebrum and Solidus, enable the development of first- and best-in-class therapies with improved safety and efficacy profiles compared to standard-of-care treatments. The company’s focus on translational tools, such as quantitative electroencephalography and novel animal models, enhances its ability to efficiently advance candidates from preclinical stages to clinical proof-of-concept.

Praxis Precision Medicines serves patients with rare and common neurological disorders, including those with essential tremor, developmental and epileptic encephalopathies, and focal onset seizures. Its customer base primarily consists of neurologists, epileptologists, and pediatric specialists who treat these conditions, as well as the patients and caregivers managing these debilitating diseases. The company’s therapies target underserved populations, such as the estimated 7,000,000 individuals in the United States with essential tremor and the 200,000 patients living with DEEs. While specific customer names are not disclosed, Praxis collaborates with healthcare providers, academic institutions, and patient advocacy groups to advance its clinical programs and ensure its therapies address the needs of the communities it serves.